Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $40

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $30 to $40.